MRSA (Methicillin-Resistant Staphylococcus aureus)
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the leading pathogens associated with hospital- and community-acquired infections worldwide. It is characterized by resistance to β-lactam antibiotics, including penicillins and cephalosporins, which limits therapeutic options and increases the complexity of clinical management.
Rapid and accurate MRSA detection is essential for infection control, outbreak prevention, and appropriate selection of antimicrobial treatment.
Staphylococcus aureus is a Gram-positive bacterium, often present on human skin and mucous membranes, and may colonize asymptomatic individuals.
Methicillin resistance occurs mainly through acquisition of the mecA gene (or less commonly mecC), which encodes the PBP2a protein (Penicillin-Binding Protein 2a). This protein has low affinity for β-lactam antibiotics, allowing the bacterium to continue synthesizing its cell wall even in the presence of these drugs.
The mecA gene is located on a mobile genetic element called SCCmec (Staphylococcal Cassette Chromosome mec), facilitating its spread among strains.
MRSA can be classified as:
HA-MRSA (Hospital-Associated MRSA) – associated with hospital settings and patients with risk factors, such as prolonged hospitalization or use of invasive devices.
CA-MRSA (Community-Associated MRSA) – associated with the community and may affect previously healthy individuals.
Transmission occurs mainly through direct contact with colonized individuals or contaminated surfaces, and proper hand hygiene is a key preventive measure.
MRSA can cause infections ranging from mild to severe and potentially fatal, including:
Skin and soft tissue infections
Abscesses
Pneumonia
Bacteremia and sepsis
Endocarditis
Medical device–related infections
Early identification is crucial to reduce complications and limit hospital spread.
Conventional diagnosis is based on bacterial culture and antimicrobial susceptibility testing. However, these methods may take 24–72 hours.
Real-Time PCR enables:
Rapid detection of the mecA/mecC gene
Simultaneous identification of Staphylococcus aureus
High sensitivity and specificity
Significant reduction in time to diagnosis
Rapid MRSA identification enables earlier clinical interventions and isolation measures.
Control strategies include:
Active screening of at-risk patients
Isolation of colonized or infected patients
Strict hand hygiene
Rational use of antimicrobials
Hospital epidemiological surveillance
Rapid molecular testing is an essential component of these programs.
MRSA infections are associated with:
Increased morbidity and mortality
Prolonged hospital stays
High hospital costs
Use of last-line antibiotics, such as vancomycin and linezolid
Effective surveillance and early diagnosis are key to minimizing these impacts.
The Bioperfectus Real-Time PCR Kit for MRSA Detection was developed to rapidly and accurately identify the presence of methicillin-resistant Staphylococcus aureus by detecting the mecA/mecC gene.
Rapid MRSA detection, reducing diagnostic time
High molecular sensitivity and specificity
Direct identification of the resistance gene (mecA/mecC)
Immediate support for therapeutic decision-making
Support for hospital infection control and outbreak prevention
By integrating the Bioperfectus Kit into laboratory routine, hospitals and diagnostic centers strengthen their infection surveillance and control strategies, enabling faster, safer, and more effective interventions.
The use of Real-Time PCR represents a strategic advance in addressing antimicrobial resistance, contributing to better clinical outcomes and greater efficiency in hospital management.
